NeuroPhage Pharmaceuticals Secures $6,400,000 New Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b5118b94-342d-4512-bb0a-51b945378589&Preview=1
Date 5/6/2013
Company Name NeuroPhage Pharmaceuticals
Mailing Address 222 3rd St. Cambridge, MA 02142
Company Description NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD.
Proceeds Purposes The new funds will help support ongoing pre-IND studies for lead compound NPT002 and will advance the development of second-generation fusion proteins with the potential for treating several neurodegenerative conditions including Alzheimer’s, Parkinson’s and Huntington’s diseases.